Latest Breaking News On - Committee for orphan medicinal products - Page 5 : comparemela.com

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

– Designation is an important step toward bringing this potentially life-changing therapy to European patients – – EU Orphan Drug Designation is the first regulatory designation for a gorilla.

Intellia Therapeutics (NTLA) Receives EU Orphan Drug Designation for NTLA-2002

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Ipsen Pharma: Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome

Positive opinion from Committee for Medicinal Products for Human Use recommending approval of Bylvay® (odevixibat) based on Phase III ASSERT clinical-trial data in Alagille syndrome (ALGS) already received in July 2023Committee for Orphan Medicinal Products confirms a negative opinion of its review recommending not to maintain the orphan designation for Bylvay in ALGSIpsen plans to submit a new Marketing Authorisation Application for the treatment of ALGS by the end of 2023 under a new brand nam